97 related articles for article (PubMed ID: 20811660)
1. Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.
Hall FL; Levy JP; Reed RA; Petchpud WN; Chua VS; Chawla SP; Gordon EM
Oncol Rep; 2010 Oct; 24(4):829-33. PubMed ID: 20811660
[TBL] [Abstract][Full Text] [Related]
2. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent.
Gordon EM; Hall FL
Int J Oncol; 2010 Jun; 36(6):1341-53. PubMed ID: 20428757
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: Rexin-G, Epeius Biotechnologies.
Morse M
Curr Opin Mol Ther; 2005 Apr; 7(2):164-9. PubMed ID: 15844625
[TBL] [Abstract][Full Text] [Related]
4. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Gordon EM; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2004 Jan; 24(1):177-85. PubMed ID: 14654955
[TBL] [Abstract][Full Text] [Related]
5. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
Gordon EM; Chan MT; Geraldino N; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2007 Jun; 30(6):1297-307. PubMed ID: 17487349
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.
Galanis E; Carlson SK; Foster NR; Lowe V; Quevedo F; McWilliams RR; Grothey A; Jatoi A; Alberts SR; Rubin J
Mol Ther; 2008 May; 16(5):979-84. PubMed ID: 18388964
[TBL] [Abstract][Full Text] [Related]
7. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.
Gordon EM; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Bruckner HW; Hall FL
Int J Oncol; 2006 Nov; 29(5):1053-64. PubMed ID: 17016635
[TBL] [Abstract][Full Text] [Related]
8. Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Chawla SP; Chua VS; Fernandez L; Quon D; Blackwelder WC; Gordon EM; Hall FL
Mol Ther; 2010 Feb; 18(2):435-41. PubMed ID: 19826403
[TBL] [Abstract][Full Text] [Related]
9. Rexin-G, a targeted genetic medicine for cancer.
Gordon EM; Hall FL
Expert Opin Biol Ther; 2010 May; 10(5):819-32. PubMed ID: 20384524
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.
Chawla SP; Chua VS; Fernandez L; Quon D; Saralou A; Blackwelder WC; Hall FL; Gordon EM
Mol Ther; 2009 Sep; 17(9):1651-7. PubMed ID: 19532136
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct.
Gordon EM; Liu PX; Chen ZH; Liu L; Whitley MD; Gee C; Groshen S; Hinton DR; Beart RW; Hall FL
Cancer Res; 2000 Jul; 60(13):3343-7. PubMed ID: 10910035
[TBL] [Abstract][Full Text] [Related]
12. Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases.
Ouyang H; Ma W; Zhang T; Liu F; Zhao L; Fang M; Quan M; Pan Z
Pancreatology; 2018 Dec; 18(8):983-989. PubMed ID: 30287168
[TBL] [Abstract][Full Text] [Related]
13. [Resolution of liver metastases in response to S-1 monotherapy in advanced pancreatic cancer--a case report].
Mizuno N; Sawaki A; Yamao K
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1511-4. PubMed ID: 17033249
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
15. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.
Pierobon M; Silvestri A; Spira A; Reeder A; Pin E; Banks S; Parasido E; Edmiston K; Liotta L; Petricoin E
J Proteome Res; 2014 Jun; 13(6):2846-55. PubMed ID: 24787230
[TBL] [Abstract][Full Text] [Related]
16. [Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer].
Ikeda M; Ueno H
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1515-9. PubMed ID: 17033250
[TBL] [Abstract][Full Text] [Related]
17. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
18. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
19. Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver.
Lenz HJ; Anderson WF; Hall FL; Gordon EM
Hum Gene Ther; 2002 Aug; 13(12):1515-37. PubMed ID: 12215272
[No Abstract] [Full Text] [Related]
20. A novel strategy for remission induction and maintenance in cancer therapy.
Tsuda H; Sata M; Ijuuin H; Kumabe T; Uchida M; Ogou Y; Akagi Y; Shirouzu K; Hara H; Nakashima Y
Oncol Rep; 2002; 9(1):65-8. PubMed ID: 11748457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
